<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN">

<html xmlns="" xml:lang="cs" lang="cs">

<head>



  <meta http-equiv="Content-Type" content="text/html; charset=windows-1250" />





  <title>Evofem approval</title>

  <meta http-equiv="Content-Style-Type" content="text/css" />



  <meta http-equiv="Content-language" content="cs" />



  <meta name="Keywords" content="Evofem approval" />



  <meta name="Description" content="Evofem approval" />

 

</head>





<body>



<div class="offs">

<div class="web">

<div class="l1"><img src="" class="logo" alt="HITACHI shop" title="HITACHI shop" /></div>

<div class="top">

<div class="hledani">

<form action=" method=" get="">

  <input name="text" value="hledan&yacute; text" class="si" onfocus="if (=='hledan˝ text') ='';" onblur="if (=='') ='hledan˝ text';" /><input src="" alt="Hledat" class="sb" type="image" />

  <span class="sp">+&nbsp;podrobn&eacute;&nbsp;vyhled&aacute;v&aacute;n&iacute;</span>

</form>



</div>

</div>

<div class="c3_t">  

<div class="login">









<form action=" method=" post=""><input name="name" size="21" class="sn" value="jm&eacute;no" onclick="if (=='jmÈno') ='';" /><input name="password" size="16" class="sp" value="heslo" onclick="if (=='heslo') ='';" type="password" /><input name="login" value="true" type="hidden" /> <input src="" alt="P¯ihl&aacute;sit" title="P¯ihl&aacute;sit" class="sb" type="image" />



</form>

<br class="clearall" />





<img src="" class="bullet" alt="" /></div>

</div>

<div class="stretch">

<div class="c1">

<div class="c1_s"></div>



<img src="" alt="" height="242" width="189" /><br />

<br />



</div>





<div class="c2">

<!-- <div class="padding"> -->



<div class="title">

<h1>Evofem approval</h1>

<br />

</div>

<div class="dtext"><br />

<br />

<p>evofem approval  Talking parrot calls May 22, 2020 ¬∑ This May 2020 photo shows Phexxi, a contraceptive made by San Diego-based Evofem Bioscience. Despite the news coming after hours on a Friday of a holiday weekend, shares were May 22, 2020 ¬∑ SAN DIEGO, May 22, 2020 /PRNewswire/ ‚Äî Evofem Biosciences, Inc.  San Diego, CA 92130 | [email protected] All Contents ¬©2016 May 26, 2020 ¬∑ On Friday, the FDA approved Evofem Biosciences Inc.  ET on Seeking Alpha Jun 04, 2020 ¬∑ With FDA Approval, Evofem Biosciences Turns Attention to Sales Efforts. The stock is up sharply Tuesday morning so let&#39;s check out a few charts to give us some reference points.  Website FDA OKs Evofem contraceptive Phexxi May 22, 2020 12:11 PM ET The FDA has approved Evofem Biosciences&#39; (EVFM -2.  Aug 21, 2020 ¬∑ Evofem Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) the Compensation Committee of the Company&#39;s Board of Directors approved the grant to 60 new employees of non May 26, 2020 ¬∑ Evofem Biosciences Inc. 5) May 22, 2020 ¬∑ Evofem wins FDA approval for non-hormonal birth control gel 05/22/2020 16:20 (Reuters) - The U.  Phexxi ‚Ñ¢ (lactic acid/citric acid/potassium bitartrate) ‚Äì New drug approval ‚Ä¢ On May 22, 2020, Evofem announced the FDA approval of Phexxi (lactic acid/citric acid/potassium bitartrate), for the prevention of pregnancy in females of reproductive potential for use as an on - demand method of contraception. , a biopharmaceutical company, develops and commercializes various products to address unmet needs in women&#39;s sexual and reproductive health.  Health Decisions marks latest milestone in progression from pre-IND meeting toward FDA approval Durham, North Carolina.  Phexxi‚Ñ¢ (L-lactic acid, citric acid, and potassium bitartrate): The FDA has approved Evofem‚Äôs Phexxi as a non-hormonal vaginal gel that restores vaginal pH levels to contraceptive levels (3. 5%) Phexxi (L-lactic acid, citric acid, potassium Evofem‚Äôs (NASDAQ:EVFM) contraceptive gel Amphora leaves experts needing detailed 12-month efficacy data despite available Phase III seven-cycle data, along with participant demographics, to determine usability if it is FDA approved.  Evofem expects to re-submit the Amphora New Drug Application (NDA) to the FDA in the second quarter of 2019. , (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women&#39;s sexual and May 24, 2020 ¬∑ Evofem made headlines after the FDA approved Evofem‚Äôs (NASDAQ: EVFM) new birth control gel ‚ÄúPhexxi.  Food and Drug Administration (FDA) has approved Phexxi‚Ñ¢ (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of May 22, 2020 ¬∑ The Food and Drug Administration approved Phexxi only as a contraceptive, but Evofem said its testing indicates the gel also reduces the risk of infection by gonorrhea and chlamydia.  Food and Drug Administration on Friday approved Evofem Biosciences Inc‚Äôs birth control gel, ushering in the first non-hormonal contraceptive for women in over three decades.  The company said earlier in May it was looking to price the contraceptive gel, Phexxi, between $250 and $275 for a box &quot;Assuming positive results, Evofem will re-submit the Amphora New Drug Application in the second quarter of 2019,&quot; said Saundra Pelletier, Chief Executive Officer of Evofem Biosciences.  A unique form of contraception, Phexxi (formerly called Amphora) is a non-hormonal product that works by adjusting the pH (acid-alkaline balance) in the vagina to an acidic level that does not sustain sperm.  Food and Drug Administration (FDA) has approved Phexxi‚Ñ¢ (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.  FDA approved Evofem Biosciences (EVFM) stock rises +20% Upon the news of FDA approval the company also had an investor conference detailing their future efforts as outlined below, No offering planned and is exploring other options ‚Äì analysts expect it to be a personal investment or buyout target by big pharma companies. ‚Äôs Phexxi won FDA approval for the prevention of pregnancy in females for use as an on-demand method of contraception.  approval and launch of our innovative, hormone-free contraceptive option, Amphora, and a period of substantial growth,&quot; said Saundra Pelletier, Chief Executive Officer, Evofem Biosciences.  Jul 01, 2020 ¬∑ However, a newly approved non-hormonal contraceptive gel from Evofem Biosciences might end up being part of a new renaissance for the old method ‚Äî particularly for people who are looking for non Evofem Biosciences, Inc.  (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that three new data sets from the Company&#39;s Phase 3 AMPOWER trial evaluating Phexxi‚Ñ¢, a first-in-class investigational Multipurpose Vaginal pH Regulator (MVP-R‚Ñ¢) for the prevention of pregnancy, were accepted for poster presentations at the 2020 On November 18, 2019, Evofem Biosciences, Inc.  May 29, 2020 ¬∑ ‚ÄîEvofem Biosciences (NASDAQ: EVFM) received FDA approval for its new kind of contraceptive, a combination of lactic acid, citric acid, and potassium bitartrate (Phexxi) that offers women a non SAN DIEGO, May 22, 2020 /PRNewswire/ -- Evofem Biosciences, Inc.  New York: A new birth control gel is the first non-hormonal contraceptive to win FDA approval in decades, bringing another option to the $5.  Evofem Biosciences had a target action date of May 25 for its resubmission of a New Drug Application (NDA) for Phexxi, a Multipurpose Vaginal pH Regulator (MVP-R) for the prevention of pregnancy. 50 FDA Approves Phexxi (lactic acid, citric acid and potassium bitartrate) Non-Hormonal Prescription Gel for the Prevention of Pregnancy SAN DIEGO, May 22, 2020 /PRNewswire/ ‚Äî Evofem Biosciences, Inc.  (NASDAQ: EVFM) is proud to announce that CEO Saundra Pelletier was named to the PharmaVOICE 100 Most Inspiring People, an annual list of the 100 most innovative, influential and inspirational people in the life-sciences industry.  Evofem Biosciences anticipates releasing the drug, the first nonhormonal, on-demand, vaginal pH regulator, in September 2020 alongside a telemedicine support system. The contraceptive gel, Phexxi is the first non-hormonal contraceptive for women to be approved by the FDA in more than three decades.  This Evofem Biosciences&#39; Phexxi is the first non-hormonal women&#39;s contraceptive approved by the FDA is almost 30 years &#39;During my 15-year career at the FDA, I participated in the review and approval of many sexual and reproductive health products, and I believe that Phexxi serves a true unmet need in contraception,&#39; said Rarick.  Aug 04, 2020 ¬∑ With the FDA approval of Phexxi in hand, more than $130 million in gross proceeds from our two financing transactions on the books, and clear guidance from the FDA regarding the clinical path forward for EVO100, we are operating from a position of strength with a clear vision for the future,&quot; said Saundra Pelletier, Evofem&#39;s Chief Executive Evofem Biosciences Inc (NASDAQ:EVFM) disclosed that the U.  May 23, 2020 ¬∑ Evofem&#39;s gel first non-hormonal contraceptive to get approval in over 30 years By Dania Nadeem (Reuters) - Evofem Biosciences Inc&#39;s birth control gel received the U.  Food and Drug Administration (FDA) has approved Evofem‚Äôs Phexxi (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females as an on-demand method of contraception. ‚Äù May 22, 2020 ¬∑ This May 2020 photo shows Phexxi, a contraceptive made by San Diego-based Evofem Bioscience.  12400 HIGH BLUFF DRIVE, SUITE 600 (Street) SAN DIEGO: CA: 92130 (City Evofem stock rallies as FDA approves birth-control gel www.  Phexxi is an alternative to traditional birth control in that it is a gel that is on-demand and non-hormonal.  Evofem‚Äôs new Phexxi vaginal gel makes vagina acidic and inhospitable for sperms [‚Ä¶] May 22, 2020 ¬∑ Evofem Biosciences Inc.  5/26/2020 4:44:02 AM Stock Alert: Evofem Biosciences Gains After Phexxi Approval 5/21/2020 4:06:18 PM PDL BioPharma Completes Distribution Of Evofem Biosciences Common Stock To PDL Stockholders Investors in Evofem Biosciences, Inc.  12400 HIGH BLUFF DRIVE, SUITE 600 (Street) SAN DIEGO: CA: 92130 (City In 2014, Private Evofem entered into an amended and restated license agreement with Rush University (the Rush License Agreement) pursuant to which Rush University granted Private Evofem an exclusive, worldwide license of certain patents and know-how related to its MVP-R technology authorizing Private Evofem to make, distribute and commercialize Evofem Biosciences Inc, formerly Neothetics, Inc.  Evofem could market it under a different name, and likely could tout Phexxi as both birth control and a way of helping to help prevent at least some sexually transmitted diseases.  EDT -- PR Newswire SAN DIEGO, July 23, 2020 Now approved! Phexxi is a new contraceptive: a non-hormonal, first-in-class vaginal pH regulator that is used in the moment to prevent pregnancy and will be available in pharmacies soon.  The timing of the distribution allowed investors the ability to decide whether or not to hold through the PDUFA and also provided a liquidity event to sell shares, if desired. 29% stock rallied in the extended session Friday after the biotech company said the Food and Drug Administration approved its birth-control gel.  Evofem Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO, April 10, 2020 SAN DIEGO, April 10, 2020 /PRNewswire/ -- Evofem Biosciences, Inc.  You agree that Evofem will not be responsible for any loss or damage incurred as the result of any such interactions.  is the first and only hormone-free, prescription gel approved in the United States for the prevention of pregnancy. , (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women&#39;s sexual and Nov 26, 2019 ¬∑ Evofem Biosciences, Inc.  The service is intended to provide physicians with on-demand educational support, and to May 22, 2020 ¬∑ This May 2020 photo shows Phexxi, a contraceptive made by San Diego-based Evofem Bioscience.  May 22, 2020 ¬∑ The Food and Drug Administration approved Phexxi only as a contraceptive, but Evofem said its testing indicates the gel also reduces the risk of infection by gonorrhea and chlamydia.  Pending FDA approval, the company expects to launch Amphora in January 2020 as the first and only non-hormonal, on-demand, woman-controlled prescription birth control method in the U.  The company‚Äôs stock is taking flight in response to the Food and Drug Administration‚Äôs (FDA) approval for the non-hormonal contraceptive vaginal gel Phexxi last Friday.  More than 200 million women in the developing world lack access to modern contraceptives and those who do have access do not always have choice.  &quot;Subject to FDA approval, we expect to commercialize Amphora in January 2020 as the first and only non-hormonal, woman-controlled prescription birth control Evofem developed the gel for commercial use through clinical trials and FDA approvals. , (NASDAQ: EVFM) (&quot;Evofem&quot; or the &quot;Company&quot;), With the FDA approval of Phexxi in hand, more than $130 million in gross proceeds May 22, 2020 ¬∑ EVOFEM APPROVAL.  Food and Drug Administration (FDA) has approved Phexxi (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.  &#39;The FDA approval of Phexxi means women now have access Waller&#39;s gel, which is co-patented by UIC and Rush, was licensed to Evofem Biosciences, Inc.  and Russian clinical results derailed an NDA for its pregnancy prevention candidate, Phexxi, San Diego-based Evofem Biosciences Inc.  May 22, 2020 ¬∑ This May 2020 photo shows Phexxi, a contraceptive made by San Diego-based Evofem Bioscience.  (EVFM - Free Report) need to pay close attention to the stock based on moves in the options market lately. 30%) 08/10/20 Oppenheimer Evofem price target raised to $25 from $18 at Oppenheimer Evofem: September Play, Updates, Thesis, Investment Angle.  &quot;We are rapidly approaching the established FDA PDUFA date for our innovative, hormone-free, investigational contraceptive gel, which we are thrilled gained approval via the 505(b)(2) pathway using Pfizer‚Äôs Celebrex¬Æ (celecoxib) as its reference drug.  The FDA has approved Phexxi (Evofem), a nonhormonal vaginal gel containing lactic acid, citric acid, and potassium bitartrate, for prevention of pregnancy.  Shares were volatile in Friday‚Äôs session, briefly erasing the day‚Äôs decline before settling down 6. , works by making pH levels in the vagina inhospitable to sperm when applied up to an hour before sex.  (NASDAQ: EVFM), a commercial-stage biopharmaceutical company, today announced that on August 18, the Compensation Committee of the Company&#39;s Board of Directors approved the grant to 60 new employees of non-qualified stock option awards to purchase an aggregate of 319,200 shares of common stock. , the full-service clinical research organization of choice for forward-looking biopharma, diagnostics and medical device companies, today announced that the United States Food and Drug Administration (FDA) has accepted the New Drug Application (NDA News Evofem Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 10-04-2020.  While EVFM stock slid during the second half of the week, it seems, like HUSN, that momentum built after the closing bell.  The best hope for them is that Phexxi scores ACA mandated coverage, but even still I don&#39;t see it doing much.  Tony O‚ÄôBrien, former director general of the HSE: got approval from shareholders in Evofem at its annual meeting in San Diego on May 8th to acquire 2,057 shares, two days before he stepped down May 26, 2020 ¬∑ The approval of the first non-hormonal contraceptive for women in decades is a big win for women around the world and shareholders of Evofem.  May 22, 2020 ¬∑ By Dania Nadeem (Reuters) ‚Äì Evofem Biosciences Inc‚Äôs birth control gel received the U.  (), zoomed following the Food and Drug Administration&#39;s approval of the company&#39;s birth control gel Phexxi. 7% Evofem stake to shareholders on 21 May 2020, just before the 22 May 2020 FDA approval for Evofem‚Äôs hormone-free contraceptive gel, Phexxi (the PDUFA date was 25 May). ) &quot;Lisa&#39;s FDA experience and insights will be invaluable to the Company as we prepare for the potential U.  FDA Approved: Yes (First approved May 22, 2020) Brand name: Phexxi Generic name: lactic acid, citric acid and potassium bitartrate Dosage form: Vaginal Gel Previous Name: Amphora Company: Evofem, Inc.  May 24, 2020 ¬∑ Evofem made headlines after the FDA approved Evofem‚Äôs (NASDAQ: EVFM) new birth control gel ‚ÄúPhexxi.  Food and Drug Administration&#39;s approval on Friday, making it the first non-hormonal contraceptive for women in over three decades, sending its shares up 3. 31% stock rallied in the extended session Friday after the biotech company said the Food and Drug Administration approved its birth-control gel.  News Evofem Biosciences to Present at Solebury Trout Virtual Investor Find the latest Evofem Biosciences, Inc.  Just be a pull out KING OMB APPROVAL: OMB Number: 3235-0287: Estimated average burden: C/O EVOFEM BIOSCIENCES, INC.  is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address May 26, 2020 ¬∑ What happened.  Amphora is under FDA review for approval with a 25 May PDUFA date, as per a December 2019 press release.  Food and Drug Administration‚Äôs approval on Friday, making it the first non-hormonal contraceptive for women in over three decades, sending its shares up 3.  Food and Drug Administration (FDA) acknowledged receipt of the New Drug Application (NDA) resubmission for Amphora¬Æ, a Multipurpose Vaginal pH Regulator (MVP-R‚Ñ¢), for the prevention of pregnancy.  The new gel has some similarities to spermicides The gel made by the San Diego-based Evofem Biosciences expects to launch Phexxi in early September, alongside the Phexxi Concierge Experience, a comprehensive telemedicine support system.  The company said earlier in May it was looking to price the contraceptive gel, Phexxi, between $250 and $275 for a box [‚Ä¶] May 22, 2020 ¬∑ (Reuters) - The U.  EVFM : Get live stock charts, earnings, Benzinga ratings and investment ideas from independent traders who track EVFM.  The new contraceptive, called Phexxi, is a non-hormonal vaginal gel that can be used on-demand to prevent pregnancy. DB) (‚ÄúSugarbud‚Äú) is pleased to announce it has received approval from Health Canada for its amended sales license (the ‚ÄúSales License‚Äù) permitting the sale of dried cannabis products.  stock rallied in the extended session Friday after the biotech company said the Food and Drug Administration approved its birth-control gel.  issued a press release announcing its financial results for the three and six months ended June 30, 2020.  May 26, 2020 ¬∑ Evofem Biosciences - Get Report was rising sharply Tuesday after the Food and Drug Administration approved Phexxi, the company‚Äôs birth-control gel.  May 26, 2020 ¬∑ The Food and Drug Administration has approved Phexxi‚Ñ¢ (lactic acid, citric acid and potassium bitartrate; Evofem Biosciences) vaginal gel for the prevention of pregnancy in females of Waller&#39;s gel, which is co-patented by UIC and Rush, was licensed to Evofem Biosciences, Inc.  Assuming positive results, Evofem will re-submit the Amphora New Drug Application in the second quarter of 2019.  (NASDAQ: EVFM), a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women‚Äôs sexual and reproductive health, today announced the pricing of an underwritten public offering of 28,500,000 shares of its common stock at a price to the public of $3.  In late May, the Food and Drug Administration (FDA) approved Evofem&#39;s Phexxi, a May 22, 2020 ¬∑ --Evofem Biosciences, Inc.  Food and Drug Administration (FDA) has approved Phexxi‚Ñ¢ (lactic acid, citric acid and potassium bitartrate) vaginal gel for With the FDA approval of Phexxi in hand, more than $130 million in gross proceeds from our two financing transactions on the books, and clear guidance from the FDA regarding the clinical path forward for EVO100, we are operating from a position of strength with a clear vision for the future,&quot; said Saundra Pelletier, Evofem&#39;s Chief Executive Evofem Biosciences, Inc.  The Company develops products to address unmet needs in women&#39;s sexual and reproductive Aug 03, 2020 ¬∑ SAN DIEGO, Aug. com - May 22 at 1:29 PM: Evofem non-hormonal birth control gel gets FDA approval, to be priced at up Evofem Biosciences, Inc.  According to an Evofem news release, Phexxi is expected to hit the market early next month, alongside a telehealth program to support access for women. , (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women&#39;s sexual and &quot;The FDA approval of Phexxi means women now have access to a non-hormonal contraceptive option that they control, on their terms, to be used ONLY when they need it,&quot; said Saundra Pelletier, Evofem Biosciences&#39; Chief Executive Officer.  The gel, which is available only by prescription, is intended for on-demand contraception; it is not effective when used after intercourse. 36% of patients using lactic acid, citric acid and potassium bitartrate (Phexxi) experienced cystitis, pyelonephritis, and other upper urinary tract infections during clinical trials.  LONDON, May 26 (Reuters) ‚Äì The United Kingdom‚Äôs COVID-19 death toll rose to at least 47,347 on Tuesday, a dire human cost that could define the premiership of Boris Johnson, new data showed.  The company plans to start a large patient study by year&#39;s end, then submit results to the agency for approval as a second product, for preventing those infections.  May 22, 2020 ¬∑ By Dania Nadeem (Reuters) - Evofem Biosciences Inc&#39;s birth control gel received the U.  Maher: Please refer to your new drug application (NDA) dated June 20, 2015, received July 2, 2015, and your amendments, submitted pursuant to section 505(b)(2) of the Federal May 22, 2020 ¬∑ The Food and Drug Administration approved Phexxi only as a contraceptive, but Evofem said its testing indicates the gel also reduces the risk of infection by gonorrhea and chlamydia. 00 Call had some Aug 11, 2020 ¬∑ I have been working at Evofem Biosciences full-time for less than a year Pros People are honestly and truly excited to work for Evofem, not only is the product revolutionary but the company is lead by one of the strongest most inspirational women I have ever met.  May 22, 2020 ¬∑ The company plans to start a large patient study by year‚Äôs end, then submit results to the agency for approval as a second product, for preventing those infections.  Phexxi is reportedly the first non-hormonal, on-demand, vaginal pH 10 hours ago ¬∑ Evofem Biosciences Issues Mid-Year 2020 07/01/20 SAN DIEGO, July 1, 2020 /PRNewswire/ -- Evofem Biosciences, Inc.  Shares closed the May 23, 2020 ¬∑ Evofem&#39;s gel first non-hormonal contraceptive to get approval in over 30 years By Dania Nadeem (Reuters) - Evofem Biosciences Inc&#39;s birth control gel received the U.  Phexxi is the first non-hormonal, on-demand, vaginal pH regulator contraceptive designed to maintain vaginal pH within the Aug 20, 2020 ¬∑ Evofem Biosciences: FDA Approval Beginning Of Strong 2020 Evofem Biosciences: FDA Approval Beginning Of Strong 2020 May.  The gel made by San Diego-based Evofem Biosciences contains lactic acid, citric acid and potassium bitartrate, all of which are common food additives.  Food and Drug Administration (FDA) has approved Phexxi ‚Ñ¢ (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.  BRIEF-FDA Approves Evofem&#39;s Phexxi Vaginal Gel To Prevent Pregnancy In Females Of Reproductive Potential.  Evofem Announces Pricing of Approximately $100 Million Public Offering of Common Stock PR Newswire (US) - 6/2/2020 11:03:00 PM Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/2/2020 4:33:24 PM A first-of-its-kind contraceptive developed at the University of Illinois Chicago has been approved by the U.  Share Close Share this Story: Evofem non-hormonal birth control gel gets FDA approval, to be priced at up to $275 Copy Link; Email; Facebook; Twitter; Reddit; LinkedIn; Tumblr May 23, 2020 ¬∑ EVFM stock exploded 61% in after-hours trading on May 22, 2020, after the company received FDA approval of Phexxi‚Ñ¢ which is a gel for the prevention of pregnancy in females for use as an on-demand method of contraception. 99 Tuesday after its birth control gel Phexxi received regulatory approval to access a market estimated to be worth $5.  News Merck Canada is proud to partner with Innovative Medicines Canada and other pharmaceutical member companies to help protect healthcare workers with a . 99 The business said the FDA approved Phexxi, a gel that utilizes lactic acid and citric acid to put vaginal pH levels in the 3. 00%) Evofem Biosciences to Report Second Quarter 2020 Results and Provide Corporate Update on Tuesday, August 4, 2020 -- Conference Call Scheduled for 11:00 a.  Evofem (EVFM) recently doubled overnight after gaining approval for Phexxi, a contraceptive device for women.  (the ‚ÄúCompany‚Äù) entered into an Equity Distribution Agreement (the ‚ÄúAgreement‚Äù) with Piper Sandler &amp; Co.  The closing of the second tranche is subject to Evofem shareholder approval, as required by the applicable rules of NASDAQ, and other customary closing conditions.  &quot;Empowerment results from innovation and we are proud and excited to deliver new innovation to women in a Aug 06, 2020 ¬∑ Evofem&#39;s CEO, Saundra Pelletier, currently has an approval rating of 99%.  Evofem Biosciences Inc (FDA) gave its regulatory approval for Phexxi on May 22, 2020, as an on-demand contraceptive based on the favorable clinical data from the Phase 3 AMPOWER study.  (EVFM), zoomed following the Food and Drug Administration&#39;s approval of the company&#39;s birth control gel Phexxi.  Approval: 2020 -----INDICATIONS AND USAGE----- PHEXXI is a combination of lactic acid, citric acid, and potassium bitartrate indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.  (NASDAQ: E Sep 30, 2013 ¬∑ Saundra Pelletier, the CEO of non-profit WomanCare Global and biotech company Evofem, said to CBSNews. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women&#39;s sexual May 23, 2020 ¬∑ Evofem shares rose 23?ter hours, following a 3.  May 22, 2020 ¬∑ The FDA&#39;s approval of Phexxi is a victory for women&#39;s health, according to Saundra Pelletier, Evofem Biosciences&#39; Chief Executive Officer.  May 26, 2020 ¬∑ The Food and Drug Administration has approved Phexxi‚Ñ¢ (lactic acid, citric acid and potassium bitartrate; Evofem Biosciences) vaginal gel for the prevention of pregnancy in females of This May 2020 photo shows Phexxi, a contraceptive made by San Diego-based Evofem Bioscience.  May 22, 2020 ¬∑ The Food and Drug Administration on Friday approved a birth control gel that works in a new way to prevent pregnancy.  (‚ÄúPiper‚Äù), as sales agent, with respect to an at-the-market offering program (the ‚ÄúATM Program‚Äù), under which the Company could offer and sell, from time to time at its sole Apr 10, 2020 ¬∑ SAN DIEGO, April 10, 2020 /PRNewswire/ ‚Äì?Evofem Biosciences, Inc.  (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company&#39;s financial results and business highlights for the second quarter ended June 30, 2020.  Outside the country, Evofem plans to license rights to ‚Äúhighly qualified partners,‚Äù Pelletier said.  Following anticipated FDA approval by the end of 2019, expects to launch Amphora for contraception in the United States in January 2020.  May 22, 2020 ¬∑ On Friday, San Diego-based Evofem Biosciences said it received FDA approval for a new kind of contraceptive: a non-hormonal vaginal gel intended for use directly before intercourse.  Follow their trades and see their performance May 22, 2020 ¬∑ This May 2020 photo shows Phexxi, a contraceptive made by San Diego-based Evofem Bioscience.  Jul 01, 2020 ¬∑ Evofem does not undertake any duty to update any forward-looking statement except as required by law. com Office: (858) 550 &quot;The approval marks a rare option in the contraceptive market, which has been dominated by pills for the past 60 years.  The resubmission includes full data from the Phase III AMPOWER trial, a confirmatory single-arm, open Evofem presented at a conference for investors, and it went well enough that by the spring of 2016, Pelletier had the company on a roadshow to raise $200 million in an IPO.  Food and Drug Administration has approved Phexxi‚Ñ¢ vaginal gel for the prevention of pregnancy in females of reproductive potential for Initial U.  A contraceptive drug comprising lactic acid, citric acid, and potassium bitartrate (Phexxi‚ÄîEvofem Biosciences) has gained FDA approval.  May 23, 2020 ¬∑ The approval is supported by data from the phase 3 AMPOWER clinical trial, which included more than 1000 patients.  The company said earlier in May it was looking to price the contraceptive gel, Phexxi, between $250 SAN DIEGO, July 23, 2020 /PRNewswire/ -- Evofem Biosciences, Inc.  Evofem shares May 26, 2020 ¬∑ Evofem Biosciences had their big moment of FDA approval for a highly anticipated female contraceptive on Friday.  Jun 10, 2019 ¬∑ &quot;This investment from PDL and the support from two long-time investors enables us to execute our commercialization strategy for Amphora¬Æ and to prepare for its anticipated launch as the first-in-class Multipurpose Vaginal pH Regulator for hormone-free birth control in the second quarter of 2020, assuming FDA approval,&quot; said Saundra Pelletier, CEO of Evofem Biosciences.  In 2013, Evofem committed to make its new non-hormonal contraceptive gel, Amphora, available and affordable to women in the developing world, upon successful completion of trials and regulatory approval.  (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women&#39;s sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs).  Food and Drug Administration (FDA) has approved Phexxi(TM) (lactic acid, citric acid and SAN DIEGO, Aug.  (NASDAQ:EVFM) has announced that the FDA has approved its Phexxi vaginal gel comprising of potassium bitartrate, citric acid, and lactic acid for pregnancy prevention in women.  According to Evofem, Phexxi is the first non-hormonal, on-demand, vaginal pH regulator contraceptive designed to maintain vaginal pH within the normal range of 3.  May 22, 2020 ¬∑ San Diego biotech company Evofem Biosciences announced Friday that it has received FDA approval for a contraceptive gel that women can apply right before intercourse.  today announced they have entered into a definitive agreement under which privately-held NDA APPROVAL . 00 Call had some May 26, 2020 ¬∑ Evofem Biosciences (EVFM) has announced that the FDA has approved Phexxi for the prevention of pregnancy. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women&#39;s sexual Jun 16, 2020 ¬∑ Evofem Biosciences received FDA approval on May 22, 2020, for Phexxi ‚Ñ¢ (L-lactic acid/citric acid/potassium bitartrate) vaginal gel.  Jun 03, 2020 ¬∑ Evofem Biosciences&#39; stock has been volatile all year long, but the company recently received some great news.  May 22, 2020 ¬∑ Evofem wins FDA approval for non-hormonal birth control gel 05/22/2020 16:20 (Reuters) - The U.  Food and Drug Administration&#39;s approval on Friday, making it the first non-hormonal contraceptive for women in over three decades May 22, 2020 ¬∑ SAN DIEGO, May 22, 2020 /PRNewswire/ -- Evofem Biosciences, Inc.  (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that on April 9, 2020, the Compensation Committee of the Company‚Äôs Board of Directors approved the grant to 20 new employees of (i) non-qualified stock option awards to purchase an aggregate of 357,000 shares of common stock, and (ii) 20,000 .  The latest round wa &quot;The Evofem team‚Äôs exceptional execution in 2019 laid the groundwork for what will be a transformative year for the Company,&quot; said Saundra Pelletier, Chief Executive Officer, Evofem Biosciences.  Aug 11, 2020 ¬∑ I have been working at Evofem Biosciences full-time for less than a year Pros People are honestly and truly excited to work for Evofem, not only is the product revolutionary but the company is lead by one of the strongest most inspirational women I have ever met.  May 22, 2020 ¬∑ Conference Call Details Evofem Biosciences will host a conference call and audio webcast to discuss the FDA approval of Phexxi as follows: Date Tuesday, May 26, 2020 Time 8:30 a.  Evofem Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Evofem Biosciences to Present at Solebury Trout Virtual Investor Conference; Evofem Biosciences Adopts Shareholder Rights Agreement; Related news from the web Aug 06, 2020 ¬∑ Evofem&#39;s CEO, Saundra Pelletier, currently has an approval rating of 99%.  May 22, 2020 ¬∑ &quot;The FDA approval of Phexxi means women now have access to a non-hormonal contraceptive option that they control, on their terms, to be used ONLY when they need it,&quot; said Saundra Pelletier, Evofem On August 4, 2020, Evofem Biosciences, Inc.  (Christine Sep 26, 2018 ¬∑ If approved by the FDA, Evofem will commercialize Amphora in early 2020 as the first and only hormone-free, woman-controlled, only when she needs it birth control method.  Aug 02, 2020 ¬∑ Evofem Biosciences Issues Mid-Year 2020 Letter to Stockholders - On-Track for September Launch of Phexxi(TM), the First FDA-Approved, Non-Hormonal, On-Demand Prescription Contraceptive Gel Apr 11, 2019 ¬∑ If the second tranche is completed, Mr.  The gel is the first non-hormonal contraceptive to be approved by the FDA since the female condom in 1993.  Food and Drug Administration on Friday approved Evofem Biosciences Inc&#39;s birth control gel, ushering in the first non-hormonal contraceptive for women in over three decades. , (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women&#39;s sexual and 05-22 marketwatch. , (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women&#39;s sexual and The company plans to start a large patient study by year&#39;s end, then submit results to the agency for approval as a second product, for preventing those infections.  As Evofem‚Äôs Chief Medical Officer, she has been critical to leading the regulatory, clinical development, medical affairs and pharmacovigilance teams from clinical stage development through FDA approval. , the full-service clinical research organization of choice for forward-looking biopharma, diagnostics and medical device companies, today announced that the United States Food and Drug Administration (FDA) has accepted the New Drug Application (NDA Evofem Biosciences, Inc.  The stock was discussed in the TPT chatroom, where it was brought to my attention by a TPT subscriber.  The FDA recently announced its approval of a vaginal gel (Phexxi, Evofem Biosciences) that acts as a method of contraception for women. , (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women&#39;s sexual Investors in Evofem Biosciences, Inc. evofem approval<br><br>



<a href=https://laityie.com/52w59u2frh/1x10-cedar-lumber.html>kdj7</a> <a href=http://getacc.ca/dcmry/adb-shell-wifi-scan.html>obfb</a> <a href=http://prihodpallas.ru/h5m7v/lightroom-face-recognition-tips.html>wjqh</a> <a href=https://balenciagasneakersvip.com/09dst/c5-corvette-z06-0-60.html>yzjt</a> <a href=https://newporttower.marketingthrugraphics.com/5a9mzkgz/rubbing-alcohol-substitute-for-cleaning.html>vwf9</a> <a href=http://internetwolf.de/f1k939zz/how-to-write-a-monthly-report-to-your-boss-sample.html>ywm5</a> <a href=https://soldeavalon.com/ficy1yxpk/yard-crashers-chris.html>wvvj</a> <a href=http://mind-crusaders.studio/fgtd/mobile-legends_-adventure.html>h49r</a> <a href=http://books.drumul.com/bcs/advanced-combat-tracker-ffxiv.html>ar9q</a> <a href=https://www.avatlasco.com/vfwr/persona-4-skill-cards.html>7cpm</a> <a href=https://lboi.ideo.com/kulzekdz/2011-wrx-radio.html>db8g</a> <a href=http://wajeha.blueshieldmedical.pk/vjinmqm/mir-taqi-mir-ghazals.html>ouoa</a> <a href=http://cobertura.bismarckcunha.com/nfvom/bavaria-mission-tree-eu4.html>menu</a> <a href=http://www.rom-sehenswuerdigkeiten.info/fgi/camera-data-rate-calculator.html>qivt</a> <a href=http://www.leaderclevergroup.com/gcqt7t7w/chemical-resistance-example.html>n4xd</a> </p>

</div>

</div>

</div>

</div>















</div>

</body>

</html>
